11/05/23 -"Good demand lead to 19.7% sales growth in 1Q23 – EBT in the mid of the guidance – Marketing expenses and personnel costs limit profitability – Unchanged guidance"
11/05/23 -"Good demand lead to 19.7% sales growth in 1Q23 – EBT in the mid of the guidance – Marketing expenses and personnel costs limit profitability – Unchanged guidance"
AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.
| Corporate broking | NO |
| Trading in corporate shares | NO |
| Analyst ownership | NO |
| Advising of corporate (strategy, marketing, debt, etc) | NO |
| Research paid for by corporate | NO |
| Provision of corporate access paid for by corporate | NO |
| Link between and a banking entity | NO |
| Brokerage activity at AlphaValue | NO |